Lynx Capital Group’s scPharmaceuticals SCPH Stock Holding History

Lynx Capital Group’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,000	Closed	-$113K	–	89
2025 Q3	$113K	Sell	20,000 -19,000	-49%	-$97.3K	0.05%	82
2025 Q2	$149K	Buy	+39,000	New	+$121K	0.07%	79

Lynx Capital Group's SCPH Position: Q4 2025 in Review

Lynx Capital Group sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 20,000 shares — an estimated $113K sold.

Lynx Capital Group first reported a position in SCPH in Q2 2025 and held it in 2 quarters. The position peaked at $149K in Q2 2025. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

Lynx Capital Group reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
Lynx Capital Group sold 20,000 scPharmaceuticals shares in Q4 2025, an estimated $113K.
Lynx Capital Group first reported a position in scPharmaceuticals in Q2 2025 and held it in 2 quarters.
Lynx Capital Group's scPharmaceuticals position peaked at $149K in Q2 2025.
0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on Lynx Capital Group's 13F filing for Q4 2025, filed 12 Aug 2026.